Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 155
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more

Conditions: Breast Cancer
Interventions: TX-plore; Device
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Cancer
Interventions: Paclitaxel, Trastuzumab, Neratinib, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 30
States / cities: Loma Linda, California • San Diego, California • Denver, Colorado + 25 more

Conditions: Advanced Solid Tumors
Interventions: ATX-898, ATX-898, fulvestrant, ribociclib; Drug
Lead sponsor: Antares Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Fort Worth, Texas • Houston, Texas • San Antonio, Texas + 2 more

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more

Conditions: MPS IIIB (Sanfilippo Syndrome)
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Moderate-Intensity Exercise; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Female only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions: IMM-6-415; Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more

Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: MEDI-573, Aromatase Inhibitor; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 34
States / cities: Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 4
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions: PEPRR, Pep-Pal; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Erythematotelangiectatic Rosacea
Interventions: The Vbeam® Prima System, Oxymetazoline HCL 1% Cream; Device · Drug
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Advanced Melanoma
Interventions: Echopulse or Echopulse HD, PolyICLC; Device · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Psoriatic Arthritis
Interventions: AbGn-168H; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more

Conditions: Breast Cancer
Interventions: Soy protein isolate, Placebo; Dietary Supplement · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 3 more

Conditions: Pharmacokinetics of ASP2408, Healthy Subjects
Interventions: ASP2408, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Text Message Application; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: FoundationDRS Solo, Standard of Care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Female Breast Cancer
Interventions: Estradiol; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Melanoma
Interventions: Obatoclax Mesylate, Temozolomide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer Female
Interventions: Internet-based Intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 236
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more

Conditions: Diabetic Polyneuropathy, Diabetic Foot Ulcer, Diabetes, Foot Infection
Interventions: TempTouch®; Device
Lead sponsor: Diabetica Solutions Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 3
States / cities: New Braunfels, Texas • San Antonio, Texas

Conditions: Breast Cancer
Interventions: adenovirus-mediated human interleukin-12; Biological
Lead sponsor: Max Sung; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

BC-DAISY: A Breast Cancer Decision Aid System

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB

Exercise Intervention in Women With Metastatic Breast Cancer

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis

Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial

Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Estrogen for Triple Negative Breast Cancer

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

TempTouch IR Thermometry & Diabetic Patient Self-Care

Gene Therapy in Treating Women With Metastatic Breast Cancer